Topics

Eisai to pull obesity drug after post-marketing study reveals increased cancer risk

10:24 EST 14 Feb 2020 | MedCity News

cancel

The voluntary withdrawal was in response to an FDA request. Eisai said its interpretation of the data differed from the agency’s, but the drug’s original developer had called off pursuit of European approval when regulators there pointed to potential tumor risk from long-term use.

Original Article: Eisai to pull obesity drug after post-marketing study reveals increased cancer risk

NEXT ARTICLE

More From BioPortfolio on "Eisai to pull obesity drug after post-marketing study reveals increased cancer risk"

Quick Search

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...